AR099856A1 - Métodos para diagnosticar y tratar la enfermedad de intestino inflamado - Google Patents
Métodos para diagnosticar y tratar la enfermedad de intestino inflamadoInfo
- Publication number
- AR099856A1 AR099856A1 ARP150100901A ARP150100901A AR099856A1 AR 099856 A1 AR099856 A1 AR 099856A1 AR P150100901 A ARP150100901 A AR P150100901A AR P150100901 A ARP150100901 A AR P150100901A AR 099856 A1 AR099856 A1 AR 099856A1
- Authority
- AR
- Argentina
- Prior art keywords
- level
- measured
- patient
- hepg
- mrna expression
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 208000028774 intestinal disease Diseases 0.000 title 1
- 108020004999 messenger RNA Proteins 0.000 abstract 9
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 abstract 4
- 238000002560 therapeutic procedure Methods 0.000 abstract 4
- 102100025618 C-X-C chemokine receptor type 6 Human genes 0.000 abstract 3
- -1 CCL4 Proteins 0.000 abstract 3
- 102100023073 Calcium-activated potassium channel subunit alpha-1 Human genes 0.000 abstract 3
- 102100030614 Carboxypeptidase A2 Human genes 0.000 abstract 3
- 108010070357 D-Aspartate Oxidase Proteins 0.000 abstract 3
- 102100039462 D-aspartate oxidase Human genes 0.000 abstract 3
- 102100040515 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial Human genes 0.000 abstract 3
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 abstract 3
- 108010008599 Forkhead Box Protein M1 Proteins 0.000 abstract 3
- 102000007237 Forkhead Box Protein M1 Human genes 0.000 abstract 3
- 102100023416 G-protein coupled receptor 15 Human genes 0.000 abstract 3
- 102100030386 Granzyme A Human genes 0.000 abstract 3
- 102100030385 Granzyme B Human genes 0.000 abstract 3
- 101000856683 Homo sapiens C-X-C chemokine receptor type 6 Proteins 0.000 abstract 3
- 101001049859 Homo sapiens Calcium-activated potassium channel subunit alpha-1 Proteins 0.000 abstract 3
- 101000966982 Homo sapiens Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial Proteins 0.000 abstract 3
- 101001027380 Homo sapiens Fibroblast growth factor 9 Proteins 0.000 abstract 3
- 101000829794 Homo sapiens G-protein coupled receptor 15 Proteins 0.000 abstract 3
- 101001009599 Homo sapiens Granzyme A Proteins 0.000 abstract 3
- 101001009603 Homo sapiens Granzyme B Proteins 0.000 abstract 3
- 101001049181 Homo sapiens Killer cell lectin-like receptor subfamily B member 1 Proteins 0.000 abstract 3
- 101000961382 Homo sapiens Mitochondrial calcium uniporter regulator 1 Proteins 0.000 abstract 3
- 101000957340 Homo sapiens Multivesicular body subunit 12B Proteins 0.000 abstract 3
- 101001071238 Homo sapiens PHD finger protein 14 Proteins 0.000 abstract 3
- 101000651291 Homo sapiens TRAF-interacting protein with FHA domain-containing protein B Proteins 0.000 abstract 3
- 101000764622 Homo sapiens Transmembrane and immunoglobulin domain-containing protein 2 Proteins 0.000 abstract 3
- 101000787917 Homo sapiens Transmembrane protein 200A Proteins 0.000 abstract 3
- 101000638161 Homo sapiens Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 abstract 3
- 102100023678 Killer cell lectin-like receptor subfamily B member 1 Human genes 0.000 abstract 3
- 102100039374 Mitochondrial calcium uniporter regulator 1 Human genes 0.000 abstract 3
- 108091006675 Monovalent cation:proton antiporter-2 Proteins 0.000 abstract 3
- 102100038748 Multivesicular body subunit 12B Human genes 0.000 abstract 3
- 102100036866 PHD finger protein 14 Human genes 0.000 abstract 3
- 102100027653 TRAF-interacting protein with FHA domain-containing protein B Human genes 0.000 abstract 3
- 102100026224 Transmembrane and immunoglobulin domain-containing protein 2 Human genes 0.000 abstract 3
- 102100025940 Transmembrane protein 200A Human genes 0.000 abstract 3
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 abstract 3
- 239000005557 antagonist Substances 0.000 abstract 3
- 102000006495 integrins Human genes 0.000 abstract 3
- 108010044426 integrins Proteins 0.000 abstract 3
- 239000000523 sample Substances 0.000 abstract 3
- 108091006255 SLC8A3 Proteins 0.000 abstract 2
- 102100032576 Sodium/calcium exchanger 3 Human genes 0.000 abstract 2
- 239000012472 biological sample Substances 0.000 abstract 2
- 229940123038 Integrin antagonist Drugs 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 239000013610 patient sample Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461971379P | 2014-03-27 | 2014-03-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099856A1 true AR099856A1 (es) | 2016-08-24 |
Family
ID=54196399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100901A AR099856A1 (es) | 2014-03-27 | 2015-03-26 | Métodos para diagnosticar y tratar la enfermedad de intestino inflamado |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10273542B2 (enExample) |
| EP (1) | EP3122377A4 (enExample) |
| JP (3) | JP7054990B2 (enExample) |
| KR (2) | KR20220065091A (enExample) |
| CN (2) | CN106102767B (enExample) |
| AR (1) | AR099856A1 (enExample) |
| AU (3) | AU2015235986B2 (enExample) |
| BR (1) | BR112016020053A2 (enExample) |
| CA (1) | CA2939246A1 (enExample) |
| IL (2) | IL247266B (enExample) |
| MA (1) | MA39804A (enExample) |
| MX (2) | MX2016012282A (enExample) |
| RU (1) | RU2016136716A (enExample) |
| SG (1) | SG11201607938UA (enExample) |
| WO (1) | WO2015148809A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100255508A1 (en) * | 2008-05-16 | 2010-10-07 | Thomas Richard Gelzleichter | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists |
| MA39804A (fr) | 2014-03-27 | 2017-02-01 | Hoffmann La Roche | Méthodes permettant le diagnostic et le traitement d'une maladie inflammatoire de l'intestin |
| JP2018507868A (ja) * | 2015-02-26 | 2018-03-22 | ジェネンテック， インコーポレイテッド | インテグリンベータ７アンタゴニスト及びクローン病の治療方法 |
| GB201611738D0 (en) * | 2016-07-05 | 2016-08-17 | Cambridge Entpr Ltd | Biomarkers for inflammatory bowel disease |
| CN107083423B (zh) * | 2017-03-27 | 2022-01-28 | 北京极客基因科技有限公司 | 一种药物靶点预测和药物全方面评价方法 |
| EP3773573A4 (en) | 2018-04-12 | 2022-04-06 | Morphic Therapeutic, Inc. | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4) (BETA7) |
| EP3884276A2 (en) * | 2018-11-23 | 2021-09-29 | Katholieke Universiteit Leuven | Predicting a treatment response in inflammatory bowel disease |
| EP3935581A4 (en) | 2019-03-04 | 2022-11-30 | Iocurrents, Inc. | DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING |
| WO2020232125A1 (en) | 2019-05-14 | 2020-11-19 | Prometheus Biosciences, Inc. | Tl1a patient selection methods, systems, and devices |
| RS66976B1 (sr) | 2019-10-16 | 2025-07-31 | Morphic Therapeutic Inc | Inhibiranje ljudskog integrina alfa4beta7 |
| US12394524B2 (en) * | 2020-07-22 | 2025-08-19 | Iterative Scopes, Inc. | Systems and methods for analysis of medical images for scoring of inflammatory bowel disease |
| EP4188958A1 (en) | 2020-07-31 | 2023-06-07 | Genentech, Inc. | Anti-integrin beta7 antibody formulations and devices |
| GB2616129A (en) * | 2020-09-01 | 2023-08-30 | Scipher Medicine Corp | Methods and systems for predicting response to anti-TNF therapies |
| EP4467573A4 (en) * | 2021-10-15 | 2025-08-06 | Yichen Therapeutics Ltd | BISPECIFIC BINDING MOLECULE |
| CN114085908B (zh) * | 2021-10-30 | 2023-08-08 | 中国人民解放军陆军军医大学第一附属医院 | 用于评估胶质母细胞瘤治疗效果的基因靶点组合及其应用 |
| AU2024282654A1 (en) | 2023-05-30 | 2025-12-04 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IL47062A (en) | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4256833A (en) | 1979-01-08 | 1981-03-17 | Majid Ali | Enzyme immunoassay for allergic disorders |
| US4665077A (en) | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| IL85746A (en) | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
| FI891226A7 (fi) | 1988-04-28 | 1989-10-29 | The Board Of Trustees Of The Leland | Anti-T-solun reseptorideterminantit autoimmuunisairauden hoitoon |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| WO1990008187A1 (en) | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
| CA2046909A1 (en) | 1989-03-21 | 1990-09-22 | Mark D. Howell | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| AU652540B2 (en) | 1989-07-19 | 1994-09-01 | Xoma Corporation | T cell receptor peptides as therapeutics for autoimmune and malignant disease |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| ATE419355T1 (de) | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Marker für krebs und biosynthetisches bindeprotein dafür |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| US6458939B1 (en) | 1996-03-15 | 2002-10-01 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| MXPA02010507A (es) | 2000-04-25 | 2003-05-14 | Idec Pharma Corp | Administracion intratecal de rituximab para el tratamiento de linfomas del sistema nervioso central. |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2005009339A2 (en) * | 2003-05-30 | 2005-02-03 | Pathway Diagnostics Corporation, Inc. (a Delaware Corporation) | Inflammatory bowel diseases |
| US20110152115A1 (en) * | 2003-09-03 | 2011-06-23 | The United States of America, as represented by the Secretary, Department of Health and | Methods for identifying, diagnosing, and predicting survival of lymphomas |
| SI1784426T1 (sl) | 2004-09-03 | 2012-03-30 | Genentech Inc | Humanizirani antagonisti proti beta in njihove uporabe |
| US8030003B2 (en) * | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
| WO2007067912A2 (en) * | 2005-12-07 | 2007-06-14 | Boehringer Ingelheim International Gmbh | Treatment and diagnostics of inflammatory diseases |
| CN101490085A (zh) * | 2006-06-12 | 2009-07-22 | 特鲁比昂药品公司 | 具有效应功能的单链多价结合蛋白 |
| WO2008028031A2 (en) * | 2006-08-30 | 2008-03-06 | Centocor, Inc. | Markers and methods for assessing and treating ulcerative colitis and related disorders using a 43 gene panel |
| WO2008088849A2 (en) * | 2007-01-16 | 2008-07-24 | Wyeth | Inflammation treatment, detection and monitoring via trem-1 |
| EP2417974A1 (en) * | 2007-02-28 | 2012-02-15 | Schering Corporation | Combination therapy for treatment of immune disorders |
| TW200848431A (en) * | 2007-06-12 | 2008-12-16 | Trubion Pharmaceuticals Inc | Single-chain multivalent binding proteins with effector function |
| BRPI0820707A2 (pt) | 2007-11-07 | 2015-06-16 | Genentech Inc | Métodos e composição para avaliar a responsividade do linfoma de células b para o tratamento com anticorpos anti-cd40 |
| AU2009215441B2 (en) * | 2008-02-19 | 2015-07-02 | The Children's Hospital Of Philadelphia | Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same |
| US20110117111A1 (en) * | 2008-03-26 | 2011-05-19 | Johns Hopkins University | Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases |
| US20100255508A1 (en) * | 2008-05-16 | 2010-10-07 | Thomas Richard Gelzleichter | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists |
| EP2347256A4 (en) * | 2008-10-09 | 2012-02-08 | Alfagene Bioscience Inc | USE AND IDENTIFICATION OF BIOMARKERS FOR GASTROINTESTINAL DISEASES |
| JP2012507723A (ja) * | 2008-11-03 | 2012-03-29 | シェーリング コーポレイション | 炎症性腸疾患生物マーカーおよび関連治療方法 |
| CA2758531C (en) * | 2009-04-14 | 2018-11-13 | Derren Barken | Inflammatory bowel disease prognostics |
| AU2010276392A1 (en) * | 2009-07-20 | 2012-03-08 | Genentech, Inc. | Gene expression markers for Crohn's disease |
| TW201138808A (en) * | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
| US8766034B2 (en) * | 2010-09-22 | 2014-07-01 | Cedars-Sinai Medical Center | TL1A model of inflammation fibrosis and autoimmunity |
| EP2668287B1 (en) * | 2011-01-25 | 2017-09-06 | TC LAND Expression | Genes and genes combinations based on gene mknk1 predictive of early response or non response of subjects suffering from rheumatoid arthritis to tnf-alpha blocking monoclonal antibody |
| CN109734807A (zh) | 2011-03-31 | 2019-05-10 | 豪夫迈·罗氏有限公司 | 施用β7整联蛋白拮抗剂的方法 |
| US20130040835A1 (en) * | 2011-05-05 | 2013-02-14 | Exagen Diagnostics, Inc | Genes predictive of anti-TNF response in inflammatory diseases |
| CN102876793B (zh) * | 2012-09-29 | 2014-03-12 | 山东省皮肤病性病防治研究所 | 单核苷酸多态性rs2058660在检测麻风病易感基因中的应用 |
| CN102876794B (zh) * | 2012-09-29 | 2014-07-02 | 山东省皮肤病性病防治研究所 | 单核苷酸多态性rs6871626在检测麻风病易感基因中的应用 |
| AU2013326921C1 (en) | 2012-10-05 | 2018-01-18 | Genentech, Inc. | Methods for diagnosing and treating inflammatory bowel disease |
| EP3495814A3 (en) | 2013-03-27 | 2019-07-17 | F. Hoffmann-La Roche AG | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists |
| MA39804A (fr) | 2014-03-27 | 2017-02-01 | Hoffmann La Roche | Méthodes permettant le diagnostic et le traitement d'une maladie inflammatoire de l'intestin |
-
2015
- 2015-03-26 MA MA039804A patent/MA39804A/fr unknown
- 2015-03-26 KR KR1020227015554A patent/KR20220065091A/ko not_active Ceased
- 2015-03-26 KR KR1020167026095A patent/KR102397324B1/ko active Active
- 2015-03-26 BR BR112016020053-5A patent/BR112016020053A2/pt not_active Application Discontinuation
- 2015-03-26 CN CN201580016240.3A patent/CN106102767B/zh not_active Expired - Fee Related
- 2015-03-26 CA CA2939246A patent/CA2939246A1/en active Pending
- 2015-03-26 MX MX2016012282A patent/MX2016012282A/es unknown
- 2015-03-26 AR ARP150100901A patent/AR099856A1/es unknown
- 2015-03-26 WO PCT/US2015/022762 patent/WO2015148809A1/en not_active Ceased
- 2015-03-26 JP JP2016559188A patent/JP7054990B2/ja active Active
- 2015-03-26 EP EP15768557.9A patent/EP3122377A4/en not_active Withdrawn
- 2015-03-26 SG SG11201607938UA patent/SG11201607938UA/en unknown
- 2015-03-26 AU AU2015235986A patent/AU2015235986B2/en not_active Ceased
- 2015-03-26 CN CN202110901698.4A patent/CN113604543A/zh active Pending
- 2015-03-26 RU RU2016136716A patent/RU2016136716A/ru not_active Application Discontinuation
-
2016
- 2016-08-14 IL IL247266A patent/IL247266B/en active IP Right Grant
- 2016-09-21 US US15/271,687 patent/US10273542B2/en active Active
- 2016-09-22 MX MX2022010809A patent/MX2022010809A/es unknown
-
2019
- 2019-03-07 US US16/295,536 patent/US10669587B2/en not_active Expired - Fee Related
- 2019-11-21 JP JP2019210883A patent/JP2020062013A/ja not_active Withdrawn
-
2020
- 2020-04-10 US US16/845,575 patent/US11261493B2/en active Active
- 2020-08-05 IL IL276516A patent/IL276516A/en unknown
-
2021
- 2021-01-28 AU AU2021200518A patent/AU2021200518B2/en not_active Ceased
- 2021-05-21 AU AU2021203296A patent/AU2021203296A1/en not_active Abandoned
- 2021-11-12 JP JP2021185176A patent/JP2022043033A/ja active Pending
-
2022
- 2022-01-20 US US17/580,357 patent/US20220186314A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR099856A1 (es) | Métodos para diagnosticar y tratar la enfermedad de intestino inflamado | |
| CY1125190T1 (el) | Χρηση ομαδων γονιδιων fgfr μεταλλαγματων στην εξακριβωση του εαν καρκινοπαθεις θα αποκρινονται σε αγωγη me fgfr αναστολεα | |
| AR095363A1 (es) | Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1 | |
| AR098155A1 (es) | Métodos para diagnosticar y tratar trastornos eosinofílicos | |
| BR112015023783A2 (pt) | método para diagnóstico e tratamento de metastase no câncer | |
| MX2021009682A (es) | Biomarcadores de cinasa 2 dependientes de ciclinas y sus usos. | |
| BR112015023120A2 (pt) | método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado | |
| AR103935A1 (es) | Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th-2 | |
| MX390772B (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
| NZ620799A (en) | Molecular diagnostic test for cancer | |
| MX373248B (es) | Prediccion de riesgo de evento cardiovascular y usos del mismo. | |
| JOP20190280A1 (ar) | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية | |
| WO2018007872A9 (en) | Biomarkers for inflammatory bowel disease | |
| MX2022005159A (es) | Uso de biomarcadores para predecir la sensibilidad clinica a 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin- 5-il)metil)-2,2-difluoroacetamida. | |
| HK1213892A1 (zh) | Tec家族激酶抑制剂疗法的伴随诊断 | |
| JP2017503481A5 (enExample) | ||
| AR080361A1 (es) | Identificacion, evaluacion y terapia de canceres con resistencia innata o adquirida a inhibidores de quinasa del linfoma anaplasico (alk) | |
| CL2021000251A1 (es) | Métodos de identificación de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa | |
| MX2017013390A (es) | Método para el tratamiento de cáncer pulmonar. | |
| MX2025004135A (es) | Predictor de radioterapia de receptor de peptido usando un ensayo de expresion genica | |
| ES2721477T3 (es) | Materiales y métodos para evaluar la progresión del cáncer de próstata | |
| AR099950A1 (es) | Determinación de polimorfismos de un solo nucleótido de utilidad para la predicción de la respuesta a la rasagilina | |
| WO2020123880A3 (en) | Genomic rearrangements associated with prostate cancer and methods of using the same | |
| PL410454A1 (pl) | Sposób identyfikowania odpowiedzi chorego na łuszczycę na leczenie genisteiną molekularny test oraz zastosowanie ekspresji genów do wykrywania in vitro łuszczycy | |
| MX2017004816A (es) | Métodos para predecir resultados clínicos en sujetos afectados con colitis ulcerosa. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |